Joseph Sullivan has been appointed to the newly created role of senior vice president of business development at Immunovaccine Inc., responsible for providing strategic and operational leadership for the company’s business development efforts. This includes expanding late stage candidate development and preparation for commercialization, as well as forging strategic commercial partnerships to support advancement of the company’s clinical assets and platform.
 
Mr. Sullivan has more than 25 years of global pharmaceutical and vaccine experience with Merck & Co. His experience includes launching two blockbuster products, licensing new indications, growing business franchises, and forming external collaborations to expand market access.
 
Mr. Sullivan has led product teams and external collaborations, identifying novel vaccine targets and technologies for development, and operationalizing global launch and commercialization plans. Most recently, he served as the executive director, Partner Strategy and Implementation Lead, at Merck. Prior to that, he led the Vaccines Product Group.
 
“Joe is a seasoned corporate development leader in the pharmaceutical and vaccine industry,” said Frederic Ors, Immunovaccine’s chief executive officer. “His experience, relationships, and reputation for strategic and operational excellence will be crucial as we move into a pivotal year for Immunovaccine. We look forward to his contributions in establishing strategic partnerships with other industry leaders as we bring our clinical lead asset towards late stage development.”